Cancer Evolution Convergence Team - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Convergence Teams

Research  >  Research Portfolio  >  Convergence Teams  >  Cancer Evolution Convergence Team

SU2C–National Science Foundation Lung Cancer Convergence Research Team:
Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment

Grant Term: September 2015–December 2018

The SU2C–National Science Foundation (NSF) Lung Cancer Convergence Research Team focuses on non-small cell lung cancer and on acute myeloid leukemia, where despite initial beneficial responses to treatment, resistance to further treatment is all too common. Mathematical modeling approaches are being used to understand the evolution of drug resistance and to develop novel therapeutic strategies aimed at keeping the cancers from adapting to treatments.

ABOUT THIS TEAM’S RESEARCH

Preclinical and clinical studies have informed the development of increasingly effective cancer therapies. However, in the majority of cases patients subsequently develop resistance to the therapies that previously worked.

This SU2C–NSF Lung Cancer Convergence Research Team comprises cancer biologists, physician scientists with expertise in clinical oncology, and mathematical modelers. Using patient samples of two cancers as test cases (acute myeloid leukemia and non-small cell lung cancer), they are investigating the dynamics of therapeutic response and resistance in patients. These models will change in response to treatment and tumor evolution, allowing investigators to computationally test possible treatment regimens and select the most promising results for examination in cell culture, mouse models, and eventually in clinical trials. This research will help scientists understand the emergence of resistance to therapies in cancer cells and test new treatments to overcome that resistance.

MEET THE TEAM

The top scientists and researchers on the SU2C–NSF Lung Cancer Convergence Research Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C–NSF Lung Cancer Convergence Research Team.

Team Members

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
Team Leader

Steven J. Altschuler, PhD
University of California, San Francisco
Team Member

Chang S. Chan, PhD
Rutgers Cancer Institute of New Jersey
Team Member

Daniel S. Fisher, PhD
Stanford University
Team Member

Aaron Hata, MD, PhD
Massachusetts General Hospital/Harvard Medical School
Team Member

Harlan Robins, PhD
Fred Hutchinson Cancer Research Center
Team Member

Lecia VanDam Sequist, MD, MPH
Massachusetts General Hospital/Harvard Medical School
Team Member

Alice Lustig
Stand Up To Cancer
Project Manager

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and six-monthly reviews by senior scientists. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click on the link to see summaries of research results so far for the SU2C–NSF Lung Cancer Convergence Research Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

Tumor Cells Can Follow Distinct Evolutionary Paths to Become Resistant to Epidermal Growth Factor Receptor Inhibition
Hata AN, Niederst MJ, Archibald HL, et al. (2016)
Nature Medicine 22(23):262-9.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE